Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study

Background: Anti-TNF alpha represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. Aims: To assess the...

ver descrição completa

Detalhes bibliográficos
Autores: Bastida, G, Marin-Jimenez, I, Fores, A, Garcia-Planella, E, Arguelles-Arias, F, Tagarro, I, Fernandez-Nistal, A, Montoto, C, Aparicio, J, Aguas, M, Santos-Fernandez, J, Bosca-Watts, M M, Ferreiro-Iglesias, R, Merino, O, Aldeguer, X, Cortes, X, Sicilia, B, Mesonero, F, Barreiro-de Acosta, M
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2022
País:España
Recursos:INCLIVA
Repositório:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p16056
Acesso em linha:https://incliva.portalinvestigacion.com/publicaciones/16056
Access Level:Acceso aberto
Palavra-chave:Anti-TNF alpha
Inflammatory bowel disease
Treatment discontinuation
Treatment intensification
id ES_4f30fafede9b09735ac4ece80407f565
oai_identifier_str oai:incliva.fundanetsuite.com:p16056
network_acronym_str ES
network_name_str España
repository_id_str
spelling Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE studyBastida, GMarin-Jimenez, IFores, AGarcia-Planella, EArguelles-Arias, FTagarro, IFernandez-Nistal, AMontoto, CAparicio, JAguas, MSantos-Fernandez, JBosca-Watts, M MFerreiro-Iglesias, RMerino, OAldeguer, XCortes, XSicilia, BMesonero, FBarreiro-de Acosta, MAnti-TNF alphaInflammatory bowel diseaseTreatment discontinuationTreatment intensificationBackground: Anti-TNF alpha represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. Aims: To assess the treatment patterns with the first anti-TNF alpha in IBD. Methods: Retrospective, observational study. Results: 310 IBD patients were analyzed along a 5-year follow-up period. 56.2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43.8% started with infliximab (IFX). 12.9% of ulcerative colitis (UC) patients initiated with ADA, while 87.1% initiated with IFX. Treatment intensification was required in 28.9% of CD and 37.1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5.3 vs. 14.3 months; p = 0.028). Treatment discontinuation due to reasons other than remission were observed in 40.7% of CD and 40.5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36.6%) than with ADA (66.7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC. Conclusions: Around one-third of IBD biologic-naive patients treated with an anti-TNF alpha required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNF alpha due to inappropriate disease control. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.ELSEVIER SCIENCE INC2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/16056DIGESTIVE AND LIVER DISEASEISSN: 15908658ISSNe: 18783562reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p160562026-06-07T16:35:31Z
dc.title.none.fl_str_mv Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study
title Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study
spellingShingle Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study
Bastida, G
Anti-TNF alpha
Inflammatory bowel disease
Treatment discontinuation
Treatment intensification
title_short Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study
title_full Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study
title_fullStr Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study
title_full_unstemmed Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study
title_sort Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study
dc.creator.none.fl_str_mv Bastida, G
Marin-Jimenez, I
Fores, A
Garcia-Planella, E
Arguelles-Arias, F
Tagarro, I
Fernandez-Nistal, A
Montoto, C
Aparicio, J
Aguas, M
Santos-Fernandez, J
Bosca-Watts, M M
Ferreiro-Iglesias, R
Merino, O
Aldeguer, X
Cortes, X
Sicilia, B
Mesonero, F
Barreiro-de Acosta, M
author Bastida, G
author_facet Bastida, G
Marin-Jimenez, I
Fores, A
Garcia-Planella, E
Arguelles-Arias, F
Tagarro, I
Fernandez-Nistal, A
Montoto, C
Aparicio, J
Aguas, M
Santos-Fernandez, J
Bosca-Watts, M M
Ferreiro-Iglesias, R
Merino, O
Aldeguer, X
Cortes, X
Sicilia, B
Mesonero, F
Barreiro-de Acosta, M
author_role author
author2 Marin-Jimenez, I
Fores, A
Garcia-Planella, E
Arguelles-Arias, F
Tagarro, I
Fernandez-Nistal, A
Montoto, C
Aparicio, J
Aguas, M
Santos-Fernandez, J
Bosca-Watts, M M
Ferreiro-Iglesias, R
Merino, O
Aldeguer, X
Cortes, X
Sicilia, B
Mesonero, F
Barreiro-de Acosta, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Anti-TNF alpha
Inflammatory bowel disease
Treatment discontinuation
Treatment intensification
topic Anti-TNF alpha
Inflammatory bowel disease
Treatment discontinuation
Treatment intensification
description Background: Anti-TNF alpha represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. Aims: To assess the treatment patterns with the first anti-TNF alpha in IBD. Methods: Retrospective, observational study. Results: 310 IBD patients were analyzed along a 5-year follow-up period. 56.2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43.8% started with infliximab (IFX). 12.9% of ulcerative colitis (UC) patients initiated with ADA, while 87.1% initiated with IFX. Treatment intensification was required in 28.9% of CD and 37.1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5.3 vs. 14.3 months; p = 0.028). Treatment discontinuation due to reasons other than remission were observed in 40.7% of CD and 40.5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36.6%) than with ADA (66.7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC. Conclusions: Around one-third of IBD biologic-naive patients treated with an anti-TNF alpha required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNF alpha due to inappropriate disease control. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/16056
url https://incliva.portalinvestigacion.com/publicaciones/16056
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCIENCE INC
publisher.none.fl_str_mv ELSEVIER SCIENCE INC
dc.source.none.fl_str_mv DIGESTIVE AND LIVER DISEASE
ISSN: 15908658
ISSNe: 18783562
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407803865563136
score 15.812429

Registros relacionados